The European Medicines Agency (EMA) recently granted Tarix Orphan’s lead investigational product TXA127 orphan drug status for the treatment of epidermolysis bullosa (EB). Orphan drug status is granted by regulatory agencies to drugs in development for the treatment of rare diseases, and where the pharmaceutical company will profit…
News
The first patient has enrolled in a clinical trial evaluating both the efficacy and safety of diacerein 1% ointment (CCP-020) in treating epidermolysis bullosa simplex (EBS), Castle Creek Pharmaceuticals recently announced. The company’s Phase 2/3 DELIVERS clinical trial (NCT03154333) is currently recruiting participants. CCP-020 is a small molecule, engineered to…
News
FDA Grants Rare Pediatric Disease Designation to EB-101 as a Treatment for Blistering Skin Disorder
The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101,  Abeona Therapeutics’ treatment for the inherited skin disease epidermolysis bullosa, or EB. Importantly, the designation also covers a severe form of the blistering and open-wound disorder known as recessive dystrophic epidermolysis bullosa, or RDEB. The FDA…
Recent Posts
- Use of vitamin A-based drug stops blistering of young girl’s fragile skin
- Why hobbies are important in life with epidermolysis bullosa
- FDA fast track status aiming to speed TolaSure Gel to fragile skin patients
- Health Canada grants priority review to Filsuvez for EB wound care
- 17 years later, I’m still learning how to navigate EB — and parenthood